ACCESS Newswire·Nov 12, 2026, 4:05 PM ET

Tenon(R) Medical Reports Third Quarter 2026 Financial Results

Tenon Medical reported third quarter 2026 revenue of $1.4 million, a 22% increase compared to the prior year.
Third quarter gross profit reached $1.0 million with a gross margin of 66.3%, up from 65.9% in the prior year period.
The company raised approximately $15.6 million in gross proceeds, repaid $5.12 million in senior convertible notes in full, and ended the quarter with $8.3 million in cash.
Tenon commenced the full commercial launch of the 3D-printed lateral screw for the SImmetry®+ SI Joint Fusion System.
The U.S. Patent and Trademark Office issued eight new patents in 2026, bringing the total issued U.S. patent portfolio to 38.
Thomas Batton Jr. was hired as Chief Revenue Officer effective October 1, 2026, to lead the commercial organization.
Initial alpha cases for the Quickstep™ Decorticator were completed on October 28, 2026, with a target for full market release in the first quarter of 2027.
The company regained compliance with Nasdaq's minimum stockholders' equity requirement and minimum bid price requirement following a 1-for-35 reverse stock split.
Operating loss for the quarter was $3.1 million, an improvement of $0.3 million compared to the third quarter of 2025.
Net loss for the third quarter totaled $6.6 million, or $5.39 per share, compared to $3.3 million in the prior year period.